| Title: |
The development of a risk threshold to aid risk stratified approach to monitoring for haematological, hepatic and/or renal adverse drug reactions during established cs DMARD treatment for systemic autoimmune rheumatic diseases: a RAND/UCLA Appropriateness Method consensus study |
| Authors: |
Ablewhite, Joanne; Nakafero, Georgina; Almayahi, Abdullah; Bechman, Katie; Ahmed, Alison; Davidson, Alan; De Vere, Hope; Dhillon, Emmandeep; Foulkes, Amy; Gullick, Nicola; Heaton, Rebecca; Hider, Samantha; Kyle, Stuart; Nowak, Kataryzna; Rose-Parfitt, Emily; Ryan, Sarah; Tan, Su Yin; Wood, Natasha; Zebate, Genevieve; Parsons, Kate; Holmes, Julia; Twohigg, Helen; Reynolds, John A; Mercer, Louise; Galloway, James; Abhishek, Abhishek |
| Contributors: |
Institute for Policy and Engagement PSF/PR via a Research England; National Institute for Health and Care Research |
| Source: |
Rheumatology ; volume 65, issue 2 ; ISSN 1462-0324 1462-0332 |
| Publisher Information: |
Oxford University Press (OUP) |
| Publication Year: |
2026 |
| Description: |
Objective To explore how appropriate different intervals between monitoring blood tests are considered in relation to the risk of clinically significant adverse drug reactions in adults prescribed conventional synthetic DMARDs (csDMARDs) for ≥1 year for systemic autoimmune rheumatic diseases (SARD). Methods A RAND/UCLA Appropriateness Method consensus study was undertaken. Members of the BSR csDMARD guideline working group who manage adults with SARD participated. Experts rated the extent to which intervals between blood tests were appropriate using Likert-type scales with responses from 1 (totally inappropriate) to 9 (totally appropriate) for nine scenarios with 5-year predicted risk of discontinuing treatment due to abnormal monitoring blood tests from 5% to 25%. Median score and the number that voted 1–3 (inappropriate), 4–6 (unsure) and 7–9 (appropriate) were calculated for every interval in each scenario. Scenarios for which agreement could not be reached in the first round were recirculated, enclosing individual round 1 response and the panel median score. Consensus that an interval was appropriate for a scenario was reached where the median panel score was ≥7 and up to six experts rated 10% over 5 years, respectively. Conclusion A threshold to aid risk-stratified monitoring during established csDMARD treatment was agreed for adults with SARD. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1093/rheumatology/keag031 |
| DOI: |
10.1093/rheumatology/keag031/66728259/keag031.pdf |
| Availability: |
https://doi.org/10.1093/rheumatology/keag031; https://academic.oup.com/rheumatology/advance-article-pdf/doi/10.1093/rheumatology/keag031/66728259/keag031.pdf; https://academic.oup.com/rheumatology/article-pdf/65/2/keag031/66728259/keag031.pdf |
| Rights: |
https://creativecommons.org/licenses/by-nc/4.0/ |
| Accession Number: |
edsbas.2A1D375D |
| Database: |
BASE |